Clinical Trial Update: Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the addition of oral azacitidine to gilteritinib salvage therapy in adults with relapsed/refractory FLT3-mutated acute myeloid…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Gilteritinib (gilteritinib)
• Oral azacitidine (azacitidine (oral formulation))

Snippet

Sponsor: French Innovative Leukemia Organisation | Conditions: AML, Adult, Refractory AML | Phase 2 | Status: RECRUITING